Donna E. Hogge

Donna E. Hogge

Auto-generated profile, based on publicly available information

Donna E. Hogge

Leukemia/BMT Program of British Columbia, Vancouver, Canada

Research Focus & Metrics

Academic Career Length

45Years (1982-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 September 2018 in Journal of Clinical Oncology
Verified
Journal Article
Open access
JLJeffrey E. Lancet
Jeffrey E. Lancet
GUGeoffrey L. Uy
Geoffrey L. Uy
JCJorge Cortes
Jorge Cortes
LNLaura F. Newell
Laura F. Newell
TLTara L. Lin
Tara L. Lin
BMBruno C. Medeiros
Bruno C. Medeiros
Purpose: CPX-351 is a dual-drug liposomal encapsulation of cytarabine and daunorubicin that delivers a synergistic 5:1 drug ratio into leukemia cells to a greater extent than normal bone marrow cells. Prior clinical studies demonstrated a sustained drug ratio and exposure in vivo and prolonged survival versus standard-of-care cytarabine plus daunorubicin chemotherapy (7+3 regimen) in older patients with newly diagnosed secondary acute myeloid leukemia (sAML). Patients and Methods: In this open-label, randomized, phase III trial, 309 patients age 60 to 75 years with newly diagnosed high-risk/sAML received one to two induction cycles of CPX-351 or 7+3 followed by consolidation therapy with a similar regimen. The primary end point was overall survival. Results: CPX-351 significantly improved median overall survival versus 7+3 (9.56 v 5.95 months; hazard ratio, 0.69; 95% CI, 0.52 to 0.90; one-sided P = .003). Overall remission rate was also significantly higher with CPX-351 versus 7+3 (47.7% v 33.3%; two-sided P = .016). Improved outcomes were observed across age-groups and AML subtypes. The incidences of nonhematologic adverse events were comparable between arms, despite a longer treatment phase and prolonged time to neutrophil and platelet count recovery with CPX-351. Early mortality rates with CPX-351 and 7+3 were 5.9% and 10.6% (two-sided P = .149) through day 30 and 13.7% and 21.2% (two-sided P = .097) through day 60. Conclusion: CPX-351 treatment is associated with significantly longer survival compared with conventional 7+3 in older adults with newly diagnosed sAML. The safety profile of CPX-351 was similar to that of conventional 7+3 therapy.

8 November 2009 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
DSDaniel T Starczynowski
Daniel T Starczynowski
FKFlorian Kuchenbauer
Florian Kuchenbauer
BABob Argiropoulos
Bob Argiropoulos
SSSandy Sung
Sandy Sung
RMRyan Morin
Ryan Morin
AKAly Karsan
Aly Karsan

1 July 2019 in The Lancet Oncology
Verified
Journal Article
Closed access
JCJorge Cortes
Jorge Cortes
SKSamer Khaled
Samer Khaled
GMGiovanni Marconi
Giovanni Marconi
APAlexander E Perl
Alexander E Perl
SGSiddhartha Ganguly
Siddhartha Ganguly
MLMark J Levis
Mark J Levis

6 December 1994 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
GSG Sauvageau
G Sauvageau
PLP M Lansdorp
P M Lansdorp
CEC J Eaves
C J Eaves
DHD E Hogge
D E Hogge
WDW H Dragowska
W H Dragowska
RHR K Humphries
R K Humphries
Class I homeobox (Hox) genes encode a major group of transcription factors controlling embryonic development and have been implicated in the continuing process of hematopoietic cell differentiation. They are clustered on four chromosomes and, in early development, exhibit spatially restricted expression with respect to their 3'-->5' chromosomal position. By using an improved PCR-based method for amplifying total cDNA derived from limited cell numbers, we now describe the expression of class I Hox genes in highly purified CD34+ cell subpopulations isolated from normal human bone marrow that represent functionally distinct stem and progenitor cell compartments. Our data indicate that at least 16 different Hox genes, mainly from the A and the B clusters, are expressed in one or more of these subpopulations of human hematopoietic cells. Moreover, markedly elevated expression of some of the Hox genes found at the 3' end of the A and B clusters (e.g., HoxB3) was a unique feature of the subpopulations that contained the most primitive functionally defined cells, whereas genes located in the 5' region of each cluster (e.g., HoxA10) were found to be expressed at nearly equal levels in the CD34+ subpopulations analyzed. In contrast to the findings for CD34+ cells, expression of two selected Hox genes, HoxB3 and HoxA10, was virtually extinguished in the CD34- fraction of bone marrow cells. These results demonstrate the expression of a broad range of Hox genes in primitive hematopoietic cells and point to the existence of a regulated program of Hox gene expression during their normal development.

22 May 2014 in Blood
Verified
Journal Article
Open access
PDF file
JLJeffrey E. Lancet
Jeffrey E. Lancet
JCJorge Cortes
Jorge Cortes
DHDonna E. Hogge
Donna E. Hogge
MTMartin S. Tallman
Martin S. Tallman
TKTibor J. Kovacsovics
Tibor J. Kovacsovics
EFEric J. Feldman
Eric J. Feldman
Key Points: First-line CPX-351 vs 7+3 control in newly diagnosed AML improves 60-day mortality, remission rate, and OS (HR = 0.46, P = .01) in sAML subset.

20 February 1996 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
APA L Petzer
A L Petzer
DHD E Hogge
D E Hogge
PLP M Landsdorp
P M Landsdorp
DRD S Reid
D S Reid
CEC J Eaves
C J Eaves
A major goal of experimental and clinical hematology is the identification of mechanisms and conditions that support the expansion of transplantable hematopoietic stem cells. In normal marrow, such cells appear to be identical to (or represent a subset of) a population referred to as long-term-culture-initiating cells (LTC-ICs) so-named because of their ability to produce colony-forming cell (CFC) progeny for > or = 5 weeks when cocultured with stromal fibroblasts. Some expansion of LTC-ICs in vitro has recently been described, but identification of the factors required and whether LTC-IC self-renewal divisions are involved have remained unresolved issues. To address these issues, we examined the maintenance and/or generation of LTC-ICs from single CD34+ CD38- cells cultured for variable periods under different culture conditions. Analysis of the progeny obtained from cultures containing a feeder layer of murine fibroblasts engineered to produce steel factor, interleukin (IL)-3, and granulocyte colony-stimulating factor showed that approximately 20% of the input LTC-ICs (representing approximately 2% of the original CD34+ CD38- cells) executed self-renewal divisions within a 6-week period. Incubation of the same CD34+ CD38- starting populations as single cells in a defined (serum free) liquid medium supplemented with Flt-3 ligand, steel factor, IL-3, IL-6, granulocyte colony-stimulating factor, and nerve growth factor resulted in the proliferation of initial cells to produce clones of from 4 to 1000 cells within 10 days, approximately 40% of which included > or = 1 LTC-IC. In contrast, in similar cultures containing methylcellulose, input LTC-ICs appeared to persist but not divide. Overall the LTC-IC expansion in the liquid cultures was 30-fold in the first 10 days and 50-fold by the end of another 1-3 weeks. Documentation of human LTC-IC self-renewal in vitro and identification of defined conditions that permit their extensive and rapid amplification should facilitate analysis of the molecular mechanisms underlying these processes and their exploitation for a variety of therapeutic applications.